| CAS NO: | 951650-22-9 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 353.42 |
|---|---|
| Formula | C23H19N3O |
| CAS No. | 951650-22-9 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: ≥ 43 mg/mL |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| SMILES Code | N#CC1=CC=CC=C1C2=CC=CC(N3C4=CC=C(C(C)(O)C)C=C4N=C3)=C2 |
| Synonyms | NS-11394; NS 11394; NS11394 |
| In Vitro | In vitro activity: NS11394 is unique in having superior efficacy at GABA(A)-alpha(3) receptors while maintaining low efficacy at GABA(A)-alpha(1) receptors. NS11394 has an excellent pharmacokinetic profile, which correlates with pharmacodynamic endpoints (CNS receptor occupancy), yielding a high level of confidence in deriving in vivo conclusions anchored to an in vitro selectivity profile and allowing for translation to higher species Kinase Assay: NS11394 is a potent and subtype-selective GABA(A) receptor-positive modulator; possesses a functional efficacy selectivity profile of alpha(5)> alpha(3)> alpha(2)> alpha(1) at GABA(A) alpha subunit-containing receptors. Cell Assay: |
|---|---|
| In Vivo | Oral administration of NS11394 (1-30 mg/kg) to rats attenuated spontaneous nociceptive behaviors in response to hindpaw injection of formalin and capsaicin, effects that were blocked by the benzodiazepine site antagonist flumazenil |
| Animal model | Mice |
| Formulation & Dosage | 1-30 mg/kg; i.v. and p.o. |
| References | J Pharmacol Exp Ther. 2008 Dec;327(3):969-81.J Pharmacol Exp Ther. 2008 Dec;327(3):954-68. |
m.cnreagent.com